0001903934-22-000001.txt : 20220118 0001903934-22-000001.hdr.sgml : 20220118 20220118132006 ACCESSION NUMBER: 0001903934-22-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b ITEM INFORMATION: Investment Company Act Section 3(c) ITEM INFORMATION: Section 3(c)(7) FILED AS OF DATE: 20220118 DATE AS OF CHANGE: 20220118 EFFECTIVENESS DATE: 20220118 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SV Biotech Crossover Opportunities Fund LP CENTRAL INDEX KEY: 0001903934 IRS NUMBER: 981618485 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-429725 FILM NUMBER: 22534586 BUSINESS ADDRESS: STREET 1: 71 KINGSWAY CITY: LONDON STATE: X0 ZIP: WC2B 6ST BUSINESS PHONE: 44 20 7421 7081 MAIL ADDRESS: STREET 1: 71 KINGSWAY CITY: LONDON STATE: X0 ZIP: WC2B 6ST D 1 primary_doc.xml X0708 D LIVE 0001903934 SV Biotech Crossover Opportunities Fund LP 71 KINGSWAY LONDON X0 UNITED KINGDOM WC2B 6ST 44 20 7421 7081 UNITED KINGDOM None None Limited Partnership true 2021 N/A SV BCO I GP LLP 71 Kingsway London X0 UNITED KINGDOM WC2B 6ST Executive Officer Director General Partner of Issuer N/A SV Health Managers LLP 71 Kingsway London X0 UNITED KINGDOM WC2B 6ST Promoter Manager of Issuer Houman Ashrafian 71 Kingsway London X0 UNITED KINGDOM WC2B 6ST Executive Officer Managing Partner Kate Bingham 71 Kingsway London X0 UNITED KINGDOM WC2B 6ST Executive Officer Managing Partner Nicola Trbovic 71 Kingsway London X0 UNITED KINGDOM WC2B 6ST Executive Officer Partner Pooled Investment Fund Venture Capital Fund false Decline to Disclose 06b 3C 3C.7 false 2021-12-31 false true true false 0 350000000 135180000 214820000 Includes subscriptions pursuant to Rule 506(b) and Regulation S. false 7 0 0 0 true The manager will receive a management fee as described in the offering documents. This amount is indeterminable at this time. false SV Biotech Crossover Opportunities Fund LP James Costine James Costine Finance Partner 2022-01-18